Global Cell and Gene Therapy Market: Focus on Products, Applications, Regions and Competitive Landscape – Analysis and Forecast, 2019-2025
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in this Report:
The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025. The cell and gene therapy market generated $1,017.2 million revenue in 2018, in terms of value.
The cell and gene therapy growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the cell and gene therapy market and favorable regulatory environment. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies. However, there are significant challenges which are restraining the market growth. These challenges include high cost of therapy and lack of therapy specific assays.
Expert Quote on the Cell and Gene Therapy Market
“The CAR-TCR drug development field has achieved huge success over the past year with regulatory approval in the U.S., Europe, Japan and Australia proving the potential these drugs have to successfully cure patients around the globe.”
Scope of the Market Intelligence on Cell and Gene Therapy Market
The cell and gene therapy market research provides a holistic view of the cell and gene therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and services allied with the therapeutics market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global cell and gene therapy market.
Market Segmentation
The cell and gene therapy market segmentation (on the basis of cell and gene therapy manufacturing) is further segmented into upstream manufacturing, and downstream manufacturing.
The cell and gene therapy market segmentation (on the basis of product) is segmented into therapeutic market and pipeline analysis.
The cell and gene therapy market segmentation (on the basis of therapeutic class) is segmented into oncology, hematology, cardiovascular, ophthalmology, neurology, and other applications.
Key Companies in the Cell and Gene Therapy Industry
The key manufacturers who have been contributing significantly to the cell and gene therapy market include Amgen Inc., bluebird bio, Inc. Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cell Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, and ViroMed Co., Ltd., among others.
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the global cell and gene therapy market?
- What are the underlying structures resulting in the emerging trends within the global cell and gene therapy market?
- How is each segment of the global cell and gene therapy market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025?
- What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2025?
- What are the key applications in global cell and gene therapy market? What are the major segments of these applications?
- Who are the key manufacturers and service providers in the global cell and gene therapy market, and what are their contributions?
The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025. The cell and gene therapy market generated $1,017.2 million revenue in 2018, in terms of value.
The cell and gene therapy growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the cell and gene therapy market and favorable regulatory environment. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies. However, there are significant challenges which are restraining the market growth. These challenges include high cost of therapy and lack of therapy specific assays.
Expert Quote on the Cell and Gene Therapy Market
“The CAR-TCR drug development field has achieved huge success over the past year with regulatory approval in the U.S., Europe, Japan and Australia proving the potential these drugs have to successfully cure patients around the globe.”
Scope of the Market Intelligence on Cell and Gene Therapy Market
The cell and gene therapy market research provides a holistic view of the cell and gene therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and services allied with the therapeutics market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global cell and gene therapy market.
Market Segmentation
The cell and gene therapy market segmentation (on the basis of cell and gene therapy manufacturing) is further segmented into upstream manufacturing, and downstream manufacturing.
The cell and gene therapy market segmentation (on the basis of product) is segmented into therapeutic market and pipeline analysis.
The cell and gene therapy market segmentation (on the basis of therapeutic class) is segmented into oncology, hematology, cardiovascular, ophthalmology, neurology, and other applications.
Key Companies in the Cell and Gene Therapy Industry
The key manufacturers who have been contributing significantly to the cell and gene therapy market include Amgen Inc., bluebird bio, Inc. Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cell Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, and ViroMed Co., Ltd., among others.
1 RESEARCH SCOPE AND METHODOLOGY
1.1 Scope of the Study
1.2 Research Methodology
1.3 Data Sources
1.4 Assumptions and Limitations
1.5 Data and Prediction Modelling
2 GLOBAL CELL AND GENE THERAPY MARKET: GLOBAL PROSPECTIVE
2.1 Introduction
2.2 Cell and Gene Therapy and Their Clinical Importance
2.3 Cell and Gene Therapy Development and Commercialization Landscape
2.4 Global Cell and Gene Therapy Market Size, 2018-2025
2.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
2.6 Reimbursement and Market Access
2.7 Key Companies in Cell and Gene Therapy Market and their Contributions
3 GLOBAL CELL AND GENE THERAPY MARKET OVERVIEW (ADDRESSABLE MARKET SIZE AND GROWTH POTENTIAL), 2018-2025
3.1 Cell and Gene Therapy Industry
3.2 Key Successful Cell and Gene Therapy Commercialization
3.3 Addressable Market and Growth Potential
3.4 North America
3.5 Europe
3.6 Asia-Pacific
3.7 Latin America
3.8 Rest-of-the-World
4 INDUSTRY INSIGHTS
4.1 Mergers and Acquisitions
4.2 Product Approvals
4.3 Partnerships, Collaborations and Joint Ventures
4.4 Business Expansion Activities and Others
4.5 Legal Requirements and Regulations
4.5.1 Overview of Regulatory Pathway for Cell and Gene Therapy
4.5.2 FDA Expedited Approval Designations
4.5.2.1 Fast Track Designation:
4.5.2.2 Breakthrough Therapy:
4.5.2.3 Accelerated Approval:
4.5.2.4 Priority Review:
4.5.2.5 Regenerative Medicine Advanced Therapy Designation:
4.5.3 Expedited Designation Vs. Traditional Approval Timelines:
4.5.4 Regulatory Challenges:
4.5.5 Successful Regulatory Strategies
5 PATENT LANDSCAPE
6 CELL AND GENE THERAPY MANUFACTURING
6.1 Viral Vector Manufacturing
6.1.1 Upstream Manufacturing
6.1.1.1 Cost Consideration and Timelines
6.1.1.2 Process Design and Regulatory Burdens
6.1.1.3 Other Considerations
6.1.1.4 Viral vector Manufacturing
6.1.1.4.1 Retrovirus
6.1.1.4.2 Lentivirus
6.1.1.4.3 AAV
6.1.1.4.4 Adenovirus
6.1.2 Downstream Manufacturing
6.1.2.1 Viral Vector Manufacturing
6.1.2.1.1 Retrovirus
6.1.2.1.2 Lentivirus
6.1.2.1.3 AAV
6.1.2.1.4 Adenovirus
6.1.2.2 Cost Considerations and Timelines
6.1.2.3 Challenges in Downstream
6.1.2.4 Scale-up of Downstream from Research to Clinical Manufacturing
6.2 Non-Viral Vector Manufacturing
6.2.1 Non-Viral, Plasmid-Free Manufacturing
6.2.2 Plasmid
6.2.3 Naked DNA
6.2.4 Physical-Mediated Methods
6.3 Cell and Gene Therapy Manufacturing Capacity, by Company
7 MARKET DYNAMICS
7.1 Impact Analysis
7.2 Market Drivers
7.2.1 Increasing Prevalence of Cancer and Chronic Diseases
7.2.2 Rising Number of Clinical Trials
7.2.3 Steady Investment and Consolidation in the Cell and Gene Therapy Market
7.2.4 Favorable Regulatory Environment
7.3 Market Restraints
7.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
7.4 Opportunities
7.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
7.5 Market Challenges
7.5.1 High Cost of Therapy
7.5.2 Lack of Therapy Specific Assays
8 GLOBAL CELL AND GENE THERAPY MARKET (BY PRODUCT)
8.1 Therapeutic Market
8.1.1 Yescarta
8.1.2 Provenge
8.1.3 Luxturna
8.1.4 Kymriah
8.1.5 Imlygic
8.1.6 Gintuit
8.1.7 MACI
8.1.8 Laviv
8.1.9 Gendicine
8.1.10 Oncorine
8.1.11 Neovasculgen
8.1.12 Strimvelis
8.1.13 Invossa
8.1.14 Others
8.2 Pipeline Analysis
8.2.1 Phase
8.2.2 Phase
8.2.3 Phase
8.2.4 Phase
9 GLOBAL CELL AND GENE THERAPY MARKET (BY THERAPEUTIC CLASS)
9.1 Rare Diseases
9.2 Oncology
9.3 Hematology
9.4 Cardiovascular
9.5 Ophthalmology
9.6 Neurology
9.7 Other Therapeutic Classes
10 GLOBAL CELL AND GENE THERAPY MARKET (BY REGION), 2018-2025 ($MILLION)
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.1.1 Approved Products
10.2.1.2 Market Size and Forecast
10.2.1.3 Key Developments
10.2.1.4 Competitive landscape
10.2.2 Canada
10.2.2.1 Approved Products
10.2.2.2 Market Size and Forecast
10.2.2.3 Key Developments
10.2.2.4 Competitive landscape
10.3 Europe
10.3.1 Germany
10.3.1.1 Approved Products
10.3.1.2 Market Size and Forecast
10.3.1.3 Key Developments
10.3.1.4 Competitive landscape
10.3.2 France
10.3.2.1 Approved Products
10.3.2.2 Market Size and Forecast
10.3.2.3 Key Developments
10.3.2.4 Competitive landscape
10.3.3 U.K.
10.3.3.1 Approved Products
10.3.3.2 Market Size and Forecast
10.3.3.3 Competitive landscape
10.3.4 Italy
10.3.4.1 Approved Products
10.3.4.2 Market Size and Forecast
10.3.4.3 Key Developments
10.3.5 Spain
10.3.5.1 Approved Products
10.3.5.2 Market Size and Forecast
10.3.5.3 Key Developments
10.3.5.4 Competitive landscape
10.3.6 The Netherlands
10.3.6.1 Approved Products
10.3.6.2 Market Size and Forecast
10.3.6.3 Key Developments
10.3.6.4 Competitive landscape
10.3.7 Russia
10.3.7.1 Approved Products
10.3.7.2 Market Size and Forecast
10.3.7.3 Competitive landscape
10.3.8 Rest-of-Europe
10.3.8.1 Market Size and Forecast
10.3.8.2 Key Developments
10.4 Asia-Pacific
10.4.1 Japan
10.4.1.1 Approved Products
10.4.1.2 Market Size and Forecast
10.4.1.3 Key Developments
10.4.1.4 Competitive landscape
10.4.1.5 China
10.4.1.6 Approved Products
10.4.1.7 Market Size and Forecast
10.4.1.8 Key Developments
10.4.1.9 Competitive landscape
10.4.2 Australia
10.4.2.1 Approved Products
10.4.2.2 Market Size and Forecast
10.4.2.3 Key Developments
10.4.3 South Korea
10.4.3.1 Approved Products
10.4.3.2 Market Size and Forecast
10.4.3.3 Key Developments
10.4.3.4 Competitive landscape
10.4.4 India
10.4.4.1 Approved Products
10.4.4.2 Market Size and Forecast
10.4.4.3 Competitive landscape
10.4.5 Singapore
10.4.5.1 Approved Products
10.4.5.2 Market Size and Forecast
10.4.5.3 Key Developments
10.4.6 Rest-of-Asia-Pacific
10.4.6.1 Market Size and Forecast
10.4.6.2 Key Developments
10.5 Latin America
10.5.1 Brazil
10.5.1.1 Market Size and Forecast
10.5.2 Mexico
10.5.2.1 Market Size and Forecast
10.5.3 Rest-of-Latin America
10.5.3.1 Market Size and Forecast
10.6 Rest-of-World
10.6.1.1 Market Size and Forecast
11 COMPETITIVE LANDSCAPE
11.1 Market Share Analysis
11.2 Growth Share Analysis
12 COMPANY PROFILES
12.1 Overview
12.2 Amgen Inc.
12.2.1 Company Overview
12.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
12.2.3 Financials
12.2.4 Key Insights about Financial Health of the Company
12.2.5 SWOT Analysis
12.3 bluebird bio, Inc.
12.3.1 Company Overview
12.3.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
12.3.3 Financials
12.3.4 Key Insights about Financial Health of the Company
12.3.5 SWOT Analysis
12.4 Dendreon Pharmaceuticals LLC.
12.4.1 Company Overview
12.4.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
12.4.3 SWOT Analysis
12.5 Fibrocell Science, Inc.
12.5.1 Company Overview
12.5.2 Role of Fibrocell Science, Inc. in the Global Cell and Gene Therapy Market
12.5.3 Key Insights about Financial Health of the Company
12.5.4 SWOT Analysis
12.6 Human Stem Cells Institute
12.6.1 Company Overview
12.6.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
12.6.3 SWOT Analysis
12.7 Kite Pharma, Inc.
12.7.1 Company Overview
12.7.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
12.7.3 Financials
12.7.4 Key Insights about Financial Health of the Company
12.7.5 SWOT Analysis
12.8 Kolon TissueGene, Inc.
12.8.1 Company Overview
12.8.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
12.8.3 SWOT Analysis
12.9 Novartis AG
12.9.1 Company Overview
12.9.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.10 Orchard Therapeutics plc.
12.10.1 Company Overview
12.10.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Organogenesis Holdings Inc.
12.11.1 Company Overview
12.11.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
12.11.3 SWOT Analysis
12.12 Pfizer, Inc.
12.12.1 Company Overview
12.12.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
12.12.3 Financials
12.12.4 Key Insights about Financial Health of the Company
12.12.5 SWOT Analysis
12.13 RENOVA THERAPEUTICS
12.13.1 Company Overview
12.13.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
12.13.3 SWOT Analysis
12.14 Shanghai Sunway Biotech Co., Ltd.,
12.14.1 Company Overview
12.14.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
12.14.3 SWOT Analysis
12.15 Sibiono GeneTech Co. Ltd.,
12.15.1 Company Overview
12.15.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
12.15.3 SWOT Analysis
12.16 Spark Therapeutics, Inc.
12.16.1 Company Overview
12.16.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
12.16.3 Financials
12.16.4 Key Insights about Financial Health of the Company
12.16.5 SWOT Analysis
12.17 Vericel Corporation
12.17.1 Company Overview
12.17.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
12.17.3 Financials
12.17.4 Key Insights About Financial Health of the Company
12.17.5 SWOT Analysis
12.18 ViroMed Co., Ltd.
12.18.1 Company Overview
12.18.2 Role of ViroMed Co., Ltd. in the Global Cell and Gene Therapy Market
12.18.3 Financials
12.18.4 SWOT Analysis
1.1 Scope of the Study
1.2 Research Methodology
1.3 Data Sources
1.4 Assumptions and Limitations
1.5 Data and Prediction Modelling
2 GLOBAL CELL AND GENE THERAPY MARKET: GLOBAL PROSPECTIVE
2.1 Introduction
2.2 Cell and Gene Therapy and Their Clinical Importance
2.3 Cell and Gene Therapy Development and Commercialization Landscape
2.4 Global Cell and Gene Therapy Market Size, 2018-2025
2.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
2.6 Reimbursement and Market Access
2.7 Key Companies in Cell and Gene Therapy Market and their Contributions
3 GLOBAL CELL AND GENE THERAPY MARKET OVERVIEW (ADDRESSABLE MARKET SIZE AND GROWTH POTENTIAL), 2018-2025
3.1 Cell and Gene Therapy Industry
3.2 Key Successful Cell and Gene Therapy Commercialization
3.3 Addressable Market and Growth Potential
3.4 North America
3.5 Europe
3.6 Asia-Pacific
3.7 Latin America
3.8 Rest-of-the-World
4 INDUSTRY INSIGHTS
4.1 Mergers and Acquisitions
4.2 Product Approvals
4.3 Partnerships, Collaborations and Joint Ventures
4.4 Business Expansion Activities and Others
4.5 Legal Requirements and Regulations
4.5.1 Overview of Regulatory Pathway for Cell and Gene Therapy
4.5.2 FDA Expedited Approval Designations
4.5.2.1 Fast Track Designation:
4.5.2.2 Breakthrough Therapy:
4.5.2.3 Accelerated Approval:
4.5.2.4 Priority Review:
4.5.2.5 Regenerative Medicine Advanced Therapy Designation:
4.5.3 Expedited Designation Vs. Traditional Approval Timelines:
4.5.4 Regulatory Challenges:
4.5.5 Successful Regulatory Strategies
5 PATENT LANDSCAPE
6 CELL AND GENE THERAPY MANUFACTURING
6.1 Viral Vector Manufacturing
6.1.1 Upstream Manufacturing
6.1.1.1 Cost Consideration and Timelines
6.1.1.2 Process Design and Regulatory Burdens
6.1.1.3 Other Considerations
6.1.1.4 Viral vector Manufacturing
6.1.1.4.1 Retrovirus
6.1.1.4.2 Lentivirus
6.1.1.4.3 AAV
6.1.1.4.4 Adenovirus
6.1.2 Downstream Manufacturing
6.1.2.1 Viral Vector Manufacturing
6.1.2.1.1 Retrovirus
6.1.2.1.2 Lentivirus
6.1.2.1.3 AAV
6.1.2.1.4 Adenovirus
6.1.2.2 Cost Considerations and Timelines
6.1.2.3 Challenges in Downstream
6.1.2.4 Scale-up of Downstream from Research to Clinical Manufacturing
6.2 Non-Viral Vector Manufacturing
6.2.1 Non-Viral, Plasmid-Free Manufacturing
6.2.2 Plasmid
6.2.3 Naked DNA
6.2.4 Physical-Mediated Methods
6.3 Cell and Gene Therapy Manufacturing Capacity, by Company
7 MARKET DYNAMICS
7.1 Impact Analysis
7.2 Market Drivers
7.2.1 Increasing Prevalence of Cancer and Chronic Diseases
7.2.2 Rising Number of Clinical Trials
7.2.3 Steady Investment and Consolidation in the Cell and Gene Therapy Market
7.2.4 Favorable Regulatory Environment
7.3 Market Restraints
7.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
7.4 Opportunities
7.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
7.5 Market Challenges
7.5.1 High Cost of Therapy
7.5.2 Lack of Therapy Specific Assays
8 GLOBAL CELL AND GENE THERAPY MARKET (BY PRODUCT)
8.1 Therapeutic Market
8.1.1 Yescarta
8.1.2 Provenge
8.1.3 Luxturna
8.1.4 Kymriah
8.1.5 Imlygic
8.1.6 Gintuit
8.1.7 MACI
8.1.8 Laviv
8.1.9 Gendicine
8.1.10 Oncorine
8.1.11 Neovasculgen
8.1.12 Strimvelis
8.1.13 Invossa
8.1.14 Others
8.2 Pipeline Analysis
8.2.1 Phase
8.2.2 Phase
8.2.3 Phase
8.2.4 Phase
9 GLOBAL CELL AND GENE THERAPY MARKET (BY THERAPEUTIC CLASS)
9.1 Rare Diseases
9.2 Oncology
9.3 Hematology
9.4 Cardiovascular
9.5 Ophthalmology
9.6 Neurology
9.7 Other Therapeutic Classes
10 GLOBAL CELL AND GENE THERAPY MARKET (BY REGION), 2018-2025 ($MILLION)
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.1.1 Approved Products
10.2.1.2 Market Size and Forecast
10.2.1.3 Key Developments
10.2.1.4 Competitive landscape
10.2.2 Canada
10.2.2.1 Approved Products
10.2.2.2 Market Size and Forecast
10.2.2.3 Key Developments
10.2.2.4 Competitive landscape
10.3 Europe
10.3.1 Germany
10.3.1.1 Approved Products
10.3.1.2 Market Size and Forecast
10.3.1.3 Key Developments
10.3.1.4 Competitive landscape
10.3.2 France
10.3.2.1 Approved Products
10.3.2.2 Market Size and Forecast
10.3.2.3 Key Developments
10.3.2.4 Competitive landscape
10.3.3 U.K.
10.3.3.1 Approved Products
10.3.3.2 Market Size and Forecast
10.3.3.3 Competitive landscape
10.3.4 Italy
10.3.4.1 Approved Products
10.3.4.2 Market Size and Forecast
10.3.4.3 Key Developments
10.3.5 Spain
10.3.5.1 Approved Products
10.3.5.2 Market Size and Forecast
10.3.5.3 Key Developments
10.3.5.4 Competitive landscape
10.3.6 The Netherlands
10.3.6.1 Approved Products
10.3.6.2 Market Size and Forecast
10.3.6.3 Key Developments
10.3.6.4 Competitive landscape
10.3.7 Russia
10.3.7.1 Approved Products
10.3.7.2 Market Size and Forecast
10.3.7.3 Competitive landscape
10.3.8 Rest-of-Europe
10.3.8.1 Market Size and Forecast
10.3.8.2 Key Developments
10.4 Asia-Pacific
10.4.1 Japan
10.4.1.1 Approved Products
10.4.1.2 Market Size and Forecast
10.4.1.3 Key Developments
10.4.1.4 Competitive landscape
10.4.1.5 China
10.4.1.6 Approved Products
10.4.1.7 Market Size and Forecast
10.4.1.8 Key Developments
10.4.1.9 Competitive landscape
10.4.2 Australia
10.4.2.1 Approved Products
10.4.2.2 Market Size and Forecast
10.4.2.3 Key Developments
10.4.3 South Korea
10.4.3.1 Approved Products
10.4.3.2 Market Size and Forecast
10.4.3.3 Key Developments
10.4.3.4 Competitive landscape
10.4.4 India
10.4.4.1 Approved Products
10.4.4.2 Market Size and Forecast
10.4.4.3 Competitive landscape
10.4.5 Singapore
10.4.5.1 Approved Products
10.4.5.2 Market Size and Forecast
10.4.5.3 Key Developments
10.4.6 Rest-of-Asia-Pacific
10.4.6.1 Market Size and Forecast
10.4.6.2 Key Developments
10.5 Latin America
10.5.1 Brazil
10.5.1.1 Market Size and Forecast
10.5.2 Mexico
10.5.2.1 Market Size and Forecast
10.5.3 Rest-of-Latin America
10.5.3.1 Market Size and Forecast
10.6 Rest-of-World
10.6.1.1 Market Size and Forecast
11 COMPETITIVE LANDSCAPE
11.1 Market Share Analysis
11.2 Growth Share Analysis
12 COMPANY PROFILES
12.1 Overview
12.2 Amgen Inc.
12.2.1 Company Overview
12.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
12.2.3 Financials
12.2.4 Key Insights about Financial Health of the Company
12.2.5 SWOT Analysis
12.3 bluebird bio, Inc.
12.3.1 Company Overview
12.3.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
12.3.3 Financials
12.3.4 Key Insights about Financial Health of the Company
12.3.5 SWOT Analysis
12.4 Dendreon Pharmaceuticals LLC.
12.4.1 Company Overview
12.4.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
12.4.3 SWOT Analysis
12.5 Fibrocell Science, Inc.
12.5.1 Company Overview
12.5.2 Role of Fibrocell Science, Inc. in the Global Cell and Gene Therapy Market
12.5.3 Key Insights about Financial Health of the Company
12.5.4 SWOT Analysis
12.6 Human Stem Cells Institute
12.6.1 Company Overview
12.6.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
12.6.3 SWOT Analysis
12.7 Kite Pharma, Inc.
12.7.1 Company Overview
12.7.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
12.7.3 Financials
12.7.4 Key Insights about Financial Health of the Company
12.7.5 SWOT Analysis
12.8 Kolon TissueGene, Inc.
12.8.1 Company Overview
12.8.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
12.8.3 SWOT Analysis
12.9 Novartis AG
12.9.1 Company Overview
12.9.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.10 Orchard Therapeutics plc.
12.10.1 Company Overview
12.10.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Organogenesis Holdings Inc.
12.11.1 Company Overview
12.11.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
12.11.3 SWOT Analysis
12.12 Pfizer, Inc.
12.12.1 Company Overview
12.12.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
12.12.3 Financials
12.12.4 Key Insights about Financial Health of the Company
12.12.5 SWOT Analysis
12.13 RENOVA THERAPEUTICS
12.13.1 Company Overview
12.13.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
12.13.3 SWOT Analysis
12.14 Shanghai Sunway Biotech Co., Ltd.,
12.14.1 Company Overview
12.14.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
12.14.3 SWOT Analysis
12.15 Sibiono GeneTech Co. Ltd.,
12.15.1 Company Overview
12.15.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
12.15.3 SWOT Analysis
12.16 Spark Therapeutics, Inc.
12.16.1 Company Overview
12.16.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
12.16.3 Financials
12.16.4 Key Insights about Financial Health of the Company
12.16.5 SWOT Analysis
12.17 Vericel Corporation
12.17.1 Company Overview
12.17.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
12.17.3 Financials
12.17.4 Key Insights About Financial Health of the Company
12.17.5 SWOT Analysis
12.18 ViroMed Co., Ltd.
12.18.1 Company Overview
12.18.2 Role of ViroMed Co., Ltd. in the Global Cell and Gene Therapy Market
12.18.3 Financials
12.18.4 SWOT Analysis
LIST OF TABLES
Table 2.1: Approved gene therapies worldwide, October 2018
Table 2.2: Product Class Inclusions in EU and US Regulatory Pathway
Table 2.3: Key Market Access Landscape (9 Countries), January 2019
Table 2.4: Key Companies in Cell and Gene Therapy Market, 2018
Table 3.1: Key Products of Cell and Gene Therapy Market
Table 6.1: Key Viral Vectors
Table 6.2: Cell and Gene Therapy Manufacturing Capacity, by Company
Table 7.1: Impact Analysis
Table 7.2: Key Cell and Gene Therapies with FDA Expedited Review
Table 8.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
Table 8.2: Key Cell and Gene Therapy Drugs in Phase 3, 2018
Table 9.1: List of Cell and Gene Therapy Medicines in Development (As of November 2018)
Table 10.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA
Table 2.1: Approved gene therapies worldwide, October 2018
Table 2.2: Product Class Inclusions in EU and US Regulatory Pathway
Table 2.3: Key Market Access Landscape (9 Countries), January 2019
Table 2.4: Key Companies in Cell and Gene Therapy Market, 2018
Table 3.1: Key Products of Cell and Gene Therapy Market
Table 6.1: Key Viral Vectors
Table 6.2: Cell and Gene Therapy Manufacturing Capacity, by Company
Table 7.1: Impact Analysis
Table 7.2: Key Cell and Gene Therapies with FDA Expedited Review
Table 8.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
Table 8.2: Key Cell and Gene Therapy Drugs in Phase 3, 2018
Table 9.1: List of Cell and Gene Therapy Medicines in Development (As of November 2018)
Table 10.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA
LIST OF FIGURES
Figure 1: Impact of Market Drivers and Market Challenges on the Global Cell and Gene Therapy Market
Figure 2: Global Cell and Gene Therapy Market Snapshot
Figure 3: Dominant Segments of the Global Cell and Gene Therapy Market, 2019 and 2025
Figure 4: Global Cell and Gene Therapy Market (by Approved Product), 2019 and 2025
Figure 5: Global Cell and Gene Therapy Market (by Therapeutic Class), 2019 and 2025
Figure 6: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
Figure 1.1: Global Cell and Gene Therapy Market Segmentation
Figure 1.2: Global Cell and Gene Therapy Market Research Methodology
Figure 1.3: Global Cell and Gene Therapy Market Research Methodology Approach
Figure 1.4: Primary Research
Figure 1.5: Secondary Research
Figure 1.6: Data Triangulation
Figure 1.7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 1.8: Top-Down Approach (Segment-Wise Analysis)
Figure 1.9: Assumptions and Limitations
Figure 1.10: Considered Factors for Data Prediction and Modelling
Figure 2.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018
Figure 2.2: Global Cell and Gene Therapy Market Size, 2018-2025
Figure 3.1: Addressable Market Size of Commercialized Products, 2018
Figure 3.2: Addressable Market Size of Commercialized Products, 2025
Figure 3.3: North America Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.4: Europe Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.6: Latin America Cell and Gene Therapy Addressable Market 2019 and 2025
Figure 4.1: Product Approvals Share (by Company), January 2016 – April 2019
Figure 4.2: Synergistic Activities Share (by Company), January 2016 – April 2019
Figure 5.1: Share of Patents (by Ownership), 2016-2019
Figure 7.1: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, by Start Date (2014-2018)
Figure 8.1: Global Cell and Gene Therapy Market, by Therapeutic Drugs, 2018-2025
Figure 8.2: Global Revenue for Yescarta, 2018-2025
Figure 8.3: Global Revenue for Provenge, 2018-2025
Figure 8.4: Global Revenue for Luxturna, 2018-2025
Figure 8.5: Global Revenue for Kymriah, 2018-2025
Figure 8.6: Global Revenue for Imlygic, 2018-2025
Figure 8.7: Global Revenue for MACI, 2018-2025
Figure 8.8: Global Revenue for Gendicine, 2018-2025
Figure 8.9: Global Revenue for Oncorine, 2018-2025
Figure 8.10: Global Revenue for Neovasculogen, 2018-2025
Figure 8.11: Global Revenue for Strimvelis, 2018-2025
Figure 8.12: Global Revenue for Invossa, 2018-2025
Figure 8.13: Global Revenue for Other Drugs, 2018-2025
Figure 8.14: Cell and Gene Therapy Medicines in Development by Disease, 2018
Figure 8.15: Cell and Gene Therapy: Breakdown of Pipeline, 2017
Figure 8.16: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2014-2018
Figure 8.17: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2014-2018
Figure 8.18: Global Cell and Gene Therapy Market, By Late Phase, 2018-2025
Figure 9.1: Global Cell and Gene Therapy Market, By Rare Diseases, 2018-2025
Figure 9.2: Global Cell and Gene Therapy Market, By Oncology, 2018-2025
Figure 9.3: Global Cell and Gene Therapy Market, By Hematology, 2018-2025
Figure 9.4: Global Cell and Gene Therapy Market, By Cardiovascular Disease, 2018-2025
Figure 9.5: Global Cell and Gene Therapy Market, By Ophthalmology, 2018-2025
Figure 9.6: Global Cell and Gene Therapy Market, By Neurology, 2018-2025
Figure 9.7: Global Cell and Gene Therapy Market, By Other Therapeutic Class, 2018-2025
Figure 10.1: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
Figure 10.2: North America Cell and Gene Therapy Market, 2018-2025
Figure 10.3: North America-Market Dynamics
Figure 10.4: U.S. Cell and Gene Therapy Market, 2018-2025
Figure 10.5: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
Figure 10.6: Canada Cell and Gene Therapy Market, 2018-2025
Figure 10.7: Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.8: Europe-Market Dynamics
Figure 10.9: Germany Cell and Gene Therapy Market, 2018-2025
Figure 10.10: France Cell and Gene Therapy Market, 2018-2025
Figure 10.11: The U.K. Cell and Gene Therapy Market, 2018-2025
Figure 10.12: Italy Cell and Gene Therapy Market, 2018-2025
Figure 10.13: Spain Cell and Gene Therapy Market, 2018-2025
Figure 10.14: The Netherlands Cell and Gene Therapy Market, 2018-2025
Figure 10.15: Russia Cell and Gene Therapy Market, 2018-2025
Figure 10.16: Rest-of-Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.17: Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.18: Asia-Pacific Market Dynamics
Figure 10.19: Japan Cell and Gene Therapy Market, 2018-2025
Figure 10.20: China Cell and Gene Therapy Market, 2018-2025
Figure 10.21: Australia Cell and Gene Therapy Market, 2018-2025
Figure 10.22: S. Korea Cell and Gene Therapy Market, 2018-2025
Figure 10.23: India Cell and Gene Therapy Market, 2018-2025
Figure 10.24: Singapore Cell and Gene Therapy Market, 2018-2025
Figure 10.25: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2018-2025
Figure 10.26: Latin America Cell and Gene Therapy Market, 2018-2025
Figure 10.27: Latin America: Market Dynamics
Figure 10.28: Brazil Cell and Gene Therapy Market, 2018-2025
Figure 10.29: Mexico Cell and Gene Therapy Market, 2018-2025
Figure 10.30: Rest-of-Latin America Cell and Gene Therapy Market, 2018-2025
Figure 10.31: Rest-of-World Cell and Gene Therapy Market, 2018-2025
Figure 11.1: Market Share Analysis for the Global Cell and Gene Therapy Market, 2018
Figure 11.2: Growth Share Matrix for Global Cell and Gene Therapy Market (by Company), 2018
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Amgen Inc.: Overall Product Portfolio
Figure 12.3: Amgen Inc.: Pipeline Product Portfolio
Figure 12.4: Amgen Inc.: Overall Financials, 2016-2018
Figure 12.5: Amgen Inc.: Revenue (by Region), 2016-2018
Figure 12.6: Amgen Inc.: R&D Expenditure, 2016-2018
Figure 12.7: Amgen Inc.: SWOT Analysis
Figure 12.8: Pipeline Product Portfolio: bluebird bio, Inc.
Figure 12.9: bluebird bio, Inc.: Overall Financials, 2016-2018
Figure 12.10: bluebird bio, Inc.: R&D Expenditure, 2016-2018
Figure 12.11: bluebird bio, Inc.: SWOT Analysis
Figure 12.12: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 12.13: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 12.14: Fibrocell Science, Inc.: Overall Product Portfolio
Figure 12.15: Fibrocell Science, Inc.: Pipeline Product Portfolio
Figure 12.16: Fibrocell Science, Inc.: R&D Expenditure, 2016-2018
Figure 12.17: Fibrocell Science, Inc.: SWOT Analysis
Figure 12.18: Human Stem Cell Institute: Overall Product Portfolio
Figure 12.19: Human Stem Cell Institute: SWOT Analysis
Figure 12.20: Kite Pharma, Inc.: Overall Product Portfolio
Figure 12.21: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 12.22: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 12.23: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 12.24: Kite Pharma, Inc.: SWOT Analysis
Figure 12.25: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 12.26: Kolon TissueGene, Inc.: SWOT Analysis
Figure 12.27: Novartis AG: Overall Product Portfolio
Figure 12.28: Novartis AG: Pipeline Product Portfolio
Figure 12.29: Novartis AG: Overall Financials, 2016-2018
Figure 12.30: Novartis AG: Revenue (by Business Segment), 2016-2018
Figure 12.31: Novartis AG: SWOT Analysis
Figure 12.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 12.33: Orchard Therapeutics plc.: Overall Financials, 2016-2018
Figure 12.34: Orchard Therapeutics plc: SWOT Analysis
Figure 12.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 12.36: Organogenesis Holdings Inc.: SWOT Analysis
Figure 12.37: Pfizer, Inc.: Pipeline Product Portfolio
Figure 12.38: Pfizer, Inc.: Overall Financials, 2016-2018
Figure 12.39: Pfizer, Inc.: Revenue (by Region), 2016-2018
Figure 12.40: Pfizer, Inc.: R&D Expenditure, 2016-2018
Figure 12.41: Pfizer, Inc.: SWOT Analysis
Figure 12.42: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 12.43: RENOVA THERAPEUTICS: SWOT Analysis
Figure 12.44: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 12.45: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 12.46: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 12.47: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 12.48: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 12.49: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 12.50: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
Figure 12.51: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
Figure 12.52: Spark Therapeutics, Inc.: SWOT Analysis
Figure 12.53: Vericel Corporation: Overall Product Portfolio
Figure 12.54: Vericel Corporation: Pipeline Product Portfolio
Figure 12.55: Vericel Corporation: Overall Financials, 2016-2018
Figure 12.56: Vericel Corporation: Revenue (by Product), 2016-2018
Figure 12.57: Vericel Corporation: R&D Expenditure (2016-2018)
Figure 12.58: Vericel Corporation: SWOT Analysis
Figure 12.59: ViroMed Co., Ltd.: Pipeline Product Portfolio
Figure 12.60: ViroMed Co: Overall Financials, 2016-2018
Figure 12.61: ViroMed Co., Ltd.: SWOT Analysis
Figure 1: Impact of Market Drivers and Market Challenges on the Global Cell and Gene Therapy Market
Figure 2: Global Cell and Gene Therapy Market Snapshot
Figure 3: Dominant Segments of the Global Cell and Gene Therapy Market, 2019 and 2025
Figure 4: Global Cell and Gene Therapy Market (by Approved Product), 2019 and 2025
Figure 5: Global Cell and Gene Therapy Market (by Therapeutic Class), 2019 and 2025
Figure 6: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
Figure 1.1: Global Cell and Gene Therapy Market Segmentation
Figure 1.2: Global Cell and Gene Therapy Market Research Methodology
Figure 1.3: Global Cell and Gene Therapy Market Research Methodology Approach
Figure 1.4: Primary Research
Figure 1.5: Secondary Research
Figure 1.6: Data Triangulation
Figure 1.7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 1.8: Top-Down Approach (Segment-Wise Analysis)
Figure 1.9: Assumptions and Limitations
Figure 1.10: Considered Factors for Data Prediction and Modelling
Figure 2.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018
Figure 2.2: Global Cell and Gene Therapy Market Size, 2018-2025
Figure 3.1: Addressable Market Size of Commercialized Products, 2018
Figure 3.2: Addressable Market Size of Commercialized Products, 2025
Figure 3.3: North America Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.4: Europe Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2018 and 2025
Figure 3.6: Latin America Cell and Gene Therapy Addressable Market 2019 and 2025
Figure 4.1: Product Approvals Share (by Company), January 2016 – April 2019
Figure 4.2: Synergistic Activities Share (by Company), January 2016 – April 2019
Figure 5.1: Share of Patents (by Ownership), 2016-2019
Figure 7.1: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, by Start Date (2014-2018)
Figure 8.1: Global Cell and Gene Therapy Market, by Therapeutic Drugs, 2018-2025
Figure 8.2: Global Revenue for Yescarta, 2018-2025
Figure 8.3: Global Revenue for Provenge, 2018-2025
Figure 8.4: Global Revenue for Luxturna, 2018-2025
Figure 8.5: Global Revenue for Kymriah, 2018-2025
Figure 8.6: Global Revenue for Imlygic, 2018-2025
Figure 8.7: Global Revenue for MACI, 2018-2025
Figure 8.8: Global Revenue for Gendicine, 2018-2025
Figure 8.9: Global Revenue for Oncorine, 2018-2025
Figure 8.10: Global Revenue for Neovasculogen, 2018-2025
Figure 8.11: Global Revenue for Strimvelis, 2018-2025
Figure 8.12: Global Revenue for Invossa, 2018-2025
Figure 8.13: Global Revenue for Other Drugs, 2018-2025
Figure 8.14: Cell and Gene Therapy Medicines in Development by Disease, 2018
Figure 8.15: Cell and Gene Therapy: Breakdown of Pipeline, 2017
Figure 8.16: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2014-2018
Figure 8.17: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2014-2018
Figure 8.18: Global Cell and Gene Therapy Market, By Late Phase, 2018-2025
Figure 9.1: Global Cell and Gene Therapy Market, By Rare Diseases, 2018-2025
Figure 9.2: Global Cell and Gene Therapy Market, By Oncology, 2018-2025
Figure 9.3: Global Cell and Gene Therapy Market, By Hematology, 2018-2025
Figure 9.4: Global Cell and Gene Therapy Market, By Cardiovascular Disease, 2018-2025
Figure 9.5: Global Cell and Gene Therapy Market, By Ophthalmology, 2018-2025
Figure 9.6: Global Cell and Gene Therapy Market, By Neurology, 2018-2025
Figure 9.7: Global Cell and Gene Therapy Market, By Other Therapeutic Class, 2018-2025
Figure 10.1: Global Cell and Gene Therapy Market (by Region), 2019 and 2025
Figure 10.2: North America Cell and Gene Therapy Market, 2018-2025
Figure 10.3: North America-Market Dynamics
Figure 10.4: U.S. Cell and Gene Therapy Market, 2018-2025
Figure 10.5: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
Figure 10.6: Canada Cell and Gene Therapy Market, 2018-2025
Figure 10.7: Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.8: Europe-Market Dynamics
Figure 10.9: Germany Cell and Gene Therapy Market, 2018-2025
Figure 10.10: France Cell and Gene Therapy Market, 2018-2025
Figure 10.11: The U.K. Cell and Gene Therapy Market, 2018-2025
Figure 10.12: Italy Cell and Gene Therapy Market, 2018-2025
Figure 10.13: Spain Cell and Gene Therapy Market, 2018-2025
Figure 10.14: The Netherlands Cell and Gene Therapy Market, 2018-2025
Figure 10.15: Russia Cell and Gene Therapy Market, 2018-2025
Figure 10.16: Rest-of-Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.17: Europe Cell and Gene Therapy Market, 2018-2025
Figure 10.18: Asia-Pacific Market Dynamics
Figure 10.19: Japan Cell and Gene Therapy Market, 2018-2025
Figure 10.20: China Cell and Gene Therapy Market, 2018-2025
Figure 10.21: Australia Cell and Gene Therapy Market, 2018-2025
Figure 10.22: S. Korea Cell and Gene Therapy Market, 2018-2025
Figure 10.23: India Cell and Gene Therapy Market, 2018-2025
Figure 10.24: Singapore Cell and Gene Therapy Market, 2018-2025
Figure 10.25: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2018-2025
Figure 10.26: Latin America Cell and Gene Therapy Market, 2018-2025
Figure 10.27: Latin America: Market Dynamics
Figure 10.28: Brazil Cell and Gene Therapy Market, 2018-2025
Figure 10.29: Mexico Cell and Gene Therapy Market, 2018-2025
Figure 10.30: Rest-of-Latin America Cell and Gene Therapy Market, 2018-2025
Figure 10.31: Rest-of-World Cell and Gene Therapy Market, 2018-2025
Figure 11.1: Market Share Analysis for the Global Cell and Gene Therapy Market, 2018
Figure 11.2: Growth Share Matrix for Global Cell and Gene Therapy Market (by Company), 2018
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Amgen Inc.: Overall Product Portfolio
Figure 12.3: Amgen Inc.: Pipeline Product Portfolio
Figure 12.4: Amgen Inc.: Overall Financials, 2016-2018
Figure 12.5: Amgen Inc.: Revenue (by Region), 2016-2018
Figure 12.6: Amgen Inc.: R&D Expenditure, 2016-2018
Figure 12.7: Amgen Inc.: SWOT Analysis
Figure 12.8: Pipeline Product Portfolio: bluebird bio, Inc.
Figure 12.9: bluebird bio, Inc.: Overall Financials, 2016-2018
Figure 12.10: bluebird bio, Inc.: R&D Expenditure, 2016-2018
Figure 12.11: bluebird bio, Inc.: SWOT Analysis
Figure 12.12: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 12.13: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 12.14: Fibrocell Science, Inc.: Overall Product Portfolio
Figure 12.15: Fibrocell Science, Inc.: Pipeline Product Portfolio
Figure 12.16: Fibrocell Science, Inc.: R&D Expenditure, 2016-2018
Figure 12.17: Fibrocell Science, Inc.: SWOT Analysis
Figure 12.18: Human Stem Cell Institute: Overall Product Portfolio
Figure 12.19: Human Stem Cell Institute: SWOT Analysis
Figure 12.20: Kite Pharma, Inc.: Overall Product Portfolio
Figure 12.21: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 12.22: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 12.23: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 12.24: Kite Pharma, Inc.: SWOT Analysis
Figure 12.25: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 12.26: Kolon TissueGene, Inc.: SWOT Analysis
Figure 12.27: Novartis AG: Overall Product Portfolio
Figure 12.28: Novartis AG: Pipeline Product Portfolio
Figure 12.29: Novartis AG: Overall Financials, 2016-2018
Figure 12.30: Novartis AG: Revenue (by Business Segment), 2016-2018
Figure 12.31: Novartis AG: SWOT Analysis
Figure 12.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 12.33: Orchard Therapeutics plc.: Overall Financials, 2016-2018
Figure 12.34: Orchard Therapeutics plc: SWOT Analysis
Figure 12.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 12.36: Organogenesis Holdings Inc.: SWOT Analysis
Figure 12.37: Pfizer, Inc.: Pipeline Product Portfolio
Figure 12.38: Pfizer, Inc.: Overall Financials, 2016-2018
Figure 12.39: Pfizer, Inc.: Revenue (by Region), 2016-2018
Figure 12.40: Pfizer, Inc.: R&D Expenditure, 2016-2018
Figure 12.41: Pfizer, Inc.: SWOT Analysis
Figure 12.42: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 12.43: RENOVA THERAPEUTICS: SWOT Analysis
Figure 12.44: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 12.45: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 12.46: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 12.47: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 12.48: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 12.49: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 12.50: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
Figure 12.51: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
Figure 12.52: Spark Therapeutics, Inc.: SWOT Analysis
Figure 12.53: Vericel Corporation: Overall Product Portfolio
Figure 12.54: Vericel Corporation: Pipeline Product Portfolio
Figure 12.55: Vericel Corporation: Overall Financials, 2016-2018
Figure 12.56: Vericel Corporation: Revenue (by Product), 2016-2018
Figure 12.57: Vericel Corporation: R&D Expenditure (2016-2018)
Figure 12.58: Vericel Corporation: SWOT Analysis
Figure 12.59: ViroMed Co., Ltd.: Pipeline Product Portfolio
Figure 12.60: ViroMed Co: Overall Financials, 2016-2018
Figure 12.61: ViroMed Co., Ltd.: SWOT Analysis
